Anti-CTLA4-based immunotherapy enhances anti-tumor responses, but severe immune-related adverse events limit its therapeutic application. Here, the authors develop ProCTLA-4, an anti-CTLA4 prodrug sensitive to matrix metalloproteinase activity, that achieves promising control over tumor growth across several preclinical mouse models while limiting systemic toxicity.
- Weian Cao
- Junfan Chen
- Wenyan Wang
